ICR welcomes MHRA approval of 'search and destroy' prostate cancer treatment 11 Aug 2022 The Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a highly targeted radioactive drug, has been approved by the medicines regulator, the MHRA, for some patients with advanced prostate cancer. Find out more Show/Hide